Breast Cancer

The FDA approved subcutaneous pembrolizumab for use in adult and pediatric solid tumor indications approved for intravenous pembrolizumab.

Two denosumab biosimilars received approval from the FDA for the purpose of increasing bone mass in individuals at high risk for fracture.

Panelists discuss how treatment approaches for patients with both ESR1 mutations and PI3K pathway alterations currently rely on single-agent elacestrant for slow-growing disease or doublet therapies for more aggressive cases, with the field rapidly evolving toward targeted combination therapies.

Panelists discuss how proteolysis-targeting chimera (PROTAC) agents such as vepdegestrant offer a different mechanism of action compared with oral selective estrogen receptor degrader (SERDs), with promising clinical activity in ESR1-mutant tumors and the need for more data on optimal sequencing strategies.

Neoadjuvant palbociclib plus endocrine therapy did not improve PEPI scores in operable hormone receptor–positive breast cancer.

Panelists discuss how longitudinal surveillance testing could enable treatment interventions based on molecular progression (ESR1 mutations) rather than waiting for radiographic progression, though questions remain about overall survival impact.

Panelists discuss how oral selective estrogen receptor degraders (SERDs) such as elacestrant are changing treatment for patients experiencing progression on CDK4/6 inhibitors, with current approval for ESR1-mutant tumors and anticipation of additional approvals for other oral SERDs in development.

Joyce O’Shaughnessy, MD, discussed data that support the use of the MammaPrint assay in predicting chemotherapy benefit in HR-positive breast cancer.

Heather McArthur, MD, MPH, FASCO, discusses data from a phase 1/2 study evaluating palazestrant in ER+, HER2– advanced or metastatic breast cancer.

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in August 2025.

In case you missed any, below is a recap of every OncLive On Air episode that aired in August 2025.

The top 5 OncLive videos of the week cover insights in lung cancer, ovarian cancer, breast cancer, and prostate cancer.

The FDA has cleared a 3-month subcutaneous depot formulation of leuprolide mesylate in prostate cancer, gedatolisib NDA is under review in breast cancer, and more.

Neelam V. Desai, MD, discusses the role of first-line CDK4/6 inhibitors in HR-positive, HER2-negative and HER2-positive metastatic breast cancer.

Neelam Desai, MD, discusses the current body of evidence for CDK 4/6 inhibitor use in metastatic HR-positive, HER2-negative breast cancer.

Tari A. King, MD, FACS, FSSO, FASCO, discusses the importance of multidisciplinary breast cancer management and the potential to de-escalate treatment.

Antoinette Tan, MD, MHS, discusses the safety profiles of ADCs and ADC selection considerations for breast cancer.

The FDA has agreed to review an NDA submission for gedatolisib in hormone receptor–positive/HER2-negative, PIK3CA wild-type advanced breast cancer.

UCSF researchers have discovered that the cells of triple-negative breast cancer tumors build molecular tunnels into nearby fat cells.

Tari A. King, MD, FACS, FSSO, FASCO, discusses locoregional breast cancer management strategies and avoiding lymph node dissection in select patients.

Findings from the Breast Cancer Weight Loss (BWEL) clinical trial set the stage for ongoing research to determine if weight loss following breast cancer treatment can reduce the risk of cancer recurrence and extend survival.

The addition of abemaciclib to endocrine therapy after surgery improved OS in patients with HR-positive, HER2-negative breast cancer with positive nodes.

Jonathan Leventhal, MD, discusses the prevalence of breast cancer treatment–associated dermatologic AEs and the need for multidisciplinary management.

Deba Sarma, MD, highlights the role of sentinel node biopsies ahead of surgery for the treatment of patients with breast cancer.